Analysed CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) News Sources
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
15-04-2026
yahoo.com
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
20-04-2026
yahoo.com
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
30-04-2026
yahoo.com
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
12-05-2026
yahoo.com
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
26-05-2026
yahoo.com
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
09-06-2026
yahoo.com
What is the current price of CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ)?
The current price of CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) is $10.38.
CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) absolute price change since previous trading day?
The absolute price change of CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) since the previous trading day is $0.32.
CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) percentage price change since previous trading day?
The percentage price change of CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) since the previous trading day is 3.1809%.
What is the most recent average sentiment score for CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ)?
The most recent average sentiment score for CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) is 60 out of 100.
What is the most recent average sentiment for CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ)?
The most recent sentiment for CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ) is .
SEC-8K** Filing Available For CARTESIAN THERAPEUTICS INC (RNAC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.